FDA Approves JANUMET XR — Merck Sharp & Dohme LLC

Merck Sharp & Dohme has received FDA approval for JANUMET XR, merging sitagliptin and metformin into an once-daily formulation expected to heighten market rivalry and streamline treatment protocols for Type 2 diabetes. This expansion of its sustained-release portfolio allows the company to defend market share by capitalizing on growing patient demand for both efficacy and long-acting convenience.